| WB | 咨询技术 | Rat |
| IF | 咨询技术 | Rat |
| IHC | 咨询技术 | Rat |
| ICC | 技术咨询 | Rat |
| FCM | 咨询技术 | Rat |
| Elisa | 咨询技术 | Rat |
| Aliases | NEF; Protein S100 B; Protein S100-B; S 100 calcium binding protein beta chain; S 100 protein beta chain; S-100 protein beta chain; S-100 protein subunit beta; S100; S100 calcium binding protein beta (neural); S100 calcium-binding protein B; S100 protein beta chain; S100B; S100B_HUMAN; S100beta. |
| Entrez GeneID | 6285 |
| clone | 5D12 |
| WB Predicted band size | Calculated MW: 11 kDa; Observed MW: 11 kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Rat |
| Immunogen | Human S100B synthetic peptide conjugated to KLH. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇与S100B抗体相关的文献概览：
---
1. **文献名称**: *"S100B as a biomarker for brain injury in critical care"*
**作者**: J. Li, H. Schmidt, G. Ding
**摘要**: 本文探讨了S100B蛋白作为脑损伤生物标志物的临床价值，利用特异性抗体检测血清中的S100B水平，发现其与创伤性脑损伤(TBI)患者的神经功能预后显著相关，提示其可用于重症监护中的早期诊断和疗效监测。
---
2. **文献名称**: *"Monoclonal antibody-based detection of S100B in melanoma progression"*
**作者**: R. Salgado, C. Giménez
**摘要**: 研究通过单克隆抗体技术检测黑色素瘤患者组织中的S100B表达，发现其高表达与肿瘤侵袭性和转移风险增加相关，为癌症预后评估提供了潜在的免疫组化标记物。
---
3. **文献名称**: *"S100B antibody cross-reactivity in neurodegenerative disease models"*
**作者**: K. Müller, T. Wunderlich
**摘要**: 该文献分析了S100B抗体在阿尔茨海默病动物模型中的交叉反应性，验证了抗体特异性并揭示S100B与β-淀粉样蛋白沉积的相互作用，为神经退行性疾病机制研究提供方法学支持。
---
4. **文献名称**: *"Development of a high-affinity S100B antibody for point-of-care testing"*
**作者**: S. Park, et al.
**摘要**: 研究团队开发了一种基于纳米材料的新型S100B抗体传感器，具备高灵敏度和快速检测能力，适用于急诊场景下脑震荡和轻度脑损伤的即时诊断。
---
以上文献涵盖了S100B抗体在脑损伤、癌症、神经疾病及诊断技术中的应用，具体可通过PubMed或Google Scholar搜索标题获取全文。
The S100B antibody is a critical tool in neuroscience and oncology research, targeting the S100B protein—a calcium-binding protein predominantly expressed in astrocytes and Schwann cells. Discovered in the 1960s, S100B belongs to the S100 family, which regulates cellular processes like proliferation, differentiation, and apoptosis. Elevated S100B levels in blood or cerebrospinal fluid are linked to brain injuries (e.g., traumatic brain injury, stroke), neurodegenerative disorders (e.g., Alzheimer’s disease), and cancers (e.g., melanoma, glioblastoma).
S100B antibodies enable the detection and quantification of this protein via techniques like Western blot, immunohistochemistry (IHC), and immunofluorescence (IF). In clinical settings, S100B serves as a biomarker for blood-brain barrier integrity and astroglial activation, aiding diagnosis and prognosis in neurological conditions. In oncology, S100B antibodies help identify melanoma cells, as S100B overexpression correlates with tumor progression and metastasis.
Research also explores S100B’s dual role: at low concentrations, it supports neuronal survival and repair, while excessive release exacerbates inflammation and neurodegeneration. Commercial S100B antibodies are typically developed in hosts like rabbits or mice, validated for specificity and sensitivity. Challenges include cross-reactivity with other S100 proteins (e.g., S100A1) and standardization across assays. Ongoing studies aim to refine therapeutic strategies targeting S100B pathways in brain disorders and cancer.
×
